Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press71010.17650/1726-9776-2018-14-1-28-35DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиNephrectomy, inferior vena cava thrombectomy in renal cell carcinoma with tumor venous thrombosis and pulmonary metastasesНефрэктомия, тромбэктомия у больных раком почки с метастазами в легкиеhttps://orcid.org/0000-0001-7754-6624VolkovaM. I.ВолковаМ. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Мария Игоревна Волкова - ведущий научный сотрудник, доктор медицинских наук.

115478 Москва, Каширское шоссе, 24

mivolkova@rambler.ruhttps://orcid.org/0000-0003-1258-0922ChernyaevV. A.ЧерняевВ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Виталий Александрович Черняев - Старший научный сотрудник, кандидат медицинских наук.

115478 Москва, Каширское шоссе, 24

Chercrc@gmail.comhttps://orcid.org/0000-0003-0727-2976KlimovA. V.КлимовА. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-0755-7421BegalievA. D.БегалиевА. Д.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-3420-7141MkhitaryanS. M.МхитарянС. М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-0644-4537OgorodnikovaE. V.ОгородниковаЕ. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-7748-9527MatveevV. B.МатвеевВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Всеволод Борисович Матвеев - заведующий отделением урологическим, Член-корреспондент РАН, профессор.

115478 Москва, Каширское шоссе, 24

vsevolodmatveev@mail.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России3003201814128352508201701022018https://oncourology.abvpress.ru/oncur/article/view/710

Objective: to assess advisability of nephrectomy, inferior vena cava (IVC) thrombectomy in renal cell carcinoma (RCC) with tumor venous thrombosis and pulmonary metastases.

Materials and methods. We analyzed medical data of 112 consecutive RCC patients with tumor venous thrombosis and pulmonary metastases undergone nephrectomy, IVC thrombectomy at N.N. Blokhin Cancer Center from 1971 to 2014. Median age was 57 (19–77) years,  a male-to-female ratio – 4.1:1. Tumor venous thrombosis occurred in all patients and achieved levels III–IV in 36 (32.1 %) cases. Ten (8.9 %) patients had solitary, 102 (91.1 %) – multiple lung metastases. Nephrectomy, thrombectomy was performed in all cases, 10 (8.9 %) patients also underwent complete resection of all pulmonary lesions. Eighty-eight (78.6 %) patients managed to receive systemic therapy. Median follow-up – 24 (3–148) months.

Results. Median operative time was 185 (70–380) min, median blood loss – 4000 (200–18 000) ml. Intraoperative complications occurred in 25 (22.3 %), postoperative – in 37 (33.0 %) patients (Clavien–Dindo grade III–V – 27 (24.1 %)). Mortality rate was 9.8 %. Five-years overall and cancer-specific survival in all patients were 22.3 and 24.0 % respectively (median – 21.0 ± 3.6 and 21.0 ± 2.9 months respectively). Independent negative prognostic factors for cancer-specific survival were tumor pulmonary embolism before surgery (hazard ratio 269.4; 95 % confidence interval 112.4–314.6; р = 0.021) and contralateral renal vein tumor thrombosis (hazard ratio 83.1; 95 % confidence interval 78.2–178.3; р = 0.011).

Conclusion. Nephrectomy, IVC thrombectomy is justified in selected RCC patients with tumor venous thrombosis and lung metastases without pulmonary embolism before surgery and contralateral renal vein tumor thrombosis. Nephrectomy, IVC thrombectomy is associated with acceptable complications rate and provides long-term survival comparable with the results of simple cytoreductive nephrectomies in historical series.

Цель: изучение непосредственных и отдаленных результатов нефрэктомии, тромбэктомии у больных раком почки с метастазами в легкие.

Материал: ретроспективно отобраны медицинские данные 112 больных раком почки с опухолевым венозным тромбозом и метастазами в легкие, подвергнутых нефрэктомии, тромбэктомии в РОНЦ им. Н.Н. Блохина  с 1971 г. по 2014 г.. Соотношение мужчин и женщин - 4,1:1. Медиана возраста - 57 (19-77) лет. У всех пациентов диагностирован рак почки с опухолевым венозным тромбозом (III-IV уровня – 36 (32,1%)) и метастазами в легкие (солитарные – 10 (8,9%)). Всем больным выполнена нефрэктомия, тромбэктомия, 10 (8,9%) пациентам удалены солитарные метастазы из легких. Лекарственное лечение получало 88 (78,6%) больных. Медиана наблюдения - 24 (3-148) месяца.

Результаты: медиана операционного времени - 185 (70-380) минут, медиана кровопотери – 4 000 (200-18 000) мл. Интраоперационные развились у 25 (22,3%), послеоперационные – у 37 (33,0%) (3-5 степени тяжести – 27 (24,1%)) больных. Летальность - 9,8%. Пятилетняя общая и специфическая выживаемость всех больных составила 22,3% и 24,0% соответственно (медиана – 21,0±3,6 месяца и 21,0±2,9 месяца соответственно). Независимыми факторами прогноза специфической выживаемости являлись ТЭЛА до операции (HR=269,4 95%СI: 112,4-314,6); р=0,021) и тромбоз контралатеральной почечной вены (HR=83,1 (95%СI: 78,2-178,3); р=0,011).

Выводы: у отобранных больных раком почки с опухолевым венозным тромбозом и метастазами в легкие нефрэктомия, тромбэктомия ассоциирована с приемлемой частотой осложнений и обеспечивает выживаемость, сопоставимую с результатами  паллиативной нефрэктомии без удаления опухолевого тромба.

Ключевые  слова: рак почки, опухолевый венозный тромбоз, метастазы в легкие, паллиативная нефрэктомия, тромбэктомия.

renal cell carcinomatumor venous thrombosispulmonary metastasescytoreductive nephrectomyinferior vena cava thrombectomyрак почкиопухолевый венозный тромбозметастазы в легкиепаллиативная нефрэктомиятромбэктомияFlanigan R.C., Salmon S.E., Blumen- stein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001;345(23):1655–9. DOI: 10.1056/NEJMoa003013. PMID: 11759643.Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345: 1655-1659.Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–70. PMID: 11583750.Mickisch GH, Garin A, van Poppel H, et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970Heng D.Y., Wells J.C., Rin B.I. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66(4):704–10. DOI: 10.1016/j.eururo.2014.05.034. PMID: 24931622.Heng, D. Y., Wells, J. C., Rini, B. I. et al.: Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 66: 704, 2014.Hanna N., Sun M., Meyer C.P. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol 2016;34(27):3267–75. DOI: 10.1200/JCO.2016.66.7931. PMID: 27325852.Hanna Nawar, Sun Maxine, Meyer Christian P. Et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study Journal of Clinical Oncology 34, no. 27 (September 2016) 3267-3275.Davydov M.I., Matveev V.B., Volkova M.I. et al. Predictors of the immediate results of thrombectomy in kidney cancer patients with venous tumor thrombosis. Oncourology = Onkourologiya 2014;(3):36–44. (In Russ.).Давыдов М.И., Матвеев В.Б., Волкова М.И. и др. Факторы прогноза непосредственных результатов тромбэктомии у больных раком почки с опухолевым венозным тромбозом. Онкоурология. – 2014. - № 3. – 36 – 44.Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9. DOI: 10.1200/JCO.2008.21.4809. PMID: 19826129.Heng Daniel Y.C., Wanling Xie, Meredith M. Regan et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Journal of Clinical Oncology 27, no. 34 (December 2009) 5794-5799.Culp S.H., Tannir N.M., Abel E.J. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116(14):3378–88. DOI: 10.1002/cncr.25046. PMID: 20564061.Culp, S. H., Tannir, N. M., Abel, E. J. et al.: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer, 116: 3378, 2010Reese A.C., Whitson J.M., Meng M.V. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol 2012;31(7):1305–9. DOI: 10.1016/j.urolonc.2011.12.006. PMID: 22237466.Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol. 2012;31:1305-1309.Whitson J.M., Reese A.C., Meng M.V. Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus. BJU Int 2011;107(5):729–34. DOI: 10.1111/j.1464-410X.2010.09593.x. PMID: 20880195.Whitson JM, Reese AC, Meng MV. Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus. BJU Int. 2011;107:729-734.Slaton J.W., Balbay M.D., Levy D.A. et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Eur Urol 1997;50(5):673–7. PMID: 9372873.Slaton JW, Derya Balbay M, Levy DA, et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Eur Urol. 1997;50:673-677Naitoh J., Kaplan A., Dorey F. et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999;162(1):46–50. DOI: 10.1097/00005392-19990700000012. PMID: 10379737.Naitoh J, Kaplan A, Dorey F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol. 1999;162: 46-50.Goetzl M.A., Goluboff E.T., Murphy A.M. et al. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: morbidity and long-term survival. Urol Oncol 2004;22(3):182–7. DOI: 10.1016/j.urolonc.2004.02.001. PMID: 15271312.Goetzl MA, Goluboff ET, Murphy AM, et al. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival. Urol Oncol. 2004;22:182-187.Zisman A., Pantuck A.J., Chao D.H. et al. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol 2002;168(3):962–7. DOI: 10.1097/01.ju.0000025144.22192.63. PMID: 12187200.Zisman A, Pantuck AJ, Chao DH, et al. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002;168: 962-967Westesson K.E., Klink J.C., Rabets J.C. et al. Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. Urology 2014;84(6): 1414–9. DOI: 10.1016/j.urology.2014.05.078. PMID: 25440988.Westesson, K. E., Klink, J. C., Rabets, J. C. et al.: Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. Urology, 84: 1414, 2014Qi N., Wu P., Chen J. et al. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience. World J Surg Oncol 2017;15(1):4. DOI: 10.1186/s12957-016-1066-3. PMID: 28056988.Qi Nienie,1 Pengjie Wu,2 Jinchao Chen, Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experienceWorld J Surg Oncol. 2017; 15: 4.Abel E.J., Spiess P.E., Margulis V. et al. Cytoreductive nephrectomy for renal cell carcinoma with venous tumor thrombus. J Urol 2017;198(2):281–8. DOI: 10.1016/j.juro.2017.03.011. PMID: 28268170.Abel EJ1, Spiess PE2, Margulis V Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Mar 6. pii: S0022-5347(17)35378-8.Janiszewska A.D., Poletajew S., Wasiutyński A. Spontaneous regression of renal cell carcinoma. Contemp Oncol (Pozn) 2013;17(2):123–7. DOI: 10.5114/wo.2013.34613. PMID: 23788977.Janiszewska Anna Daria, Poletajew Sławomir ,Wasiutyński Aleksander Spontaneous regression of renal cell carcinomaContemp Oncol (Pozn). 2013; 17(2): 123–127Shuch B., Riggs S.B., LaRochelle J.C. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008;102(6):692–6. DOI: 10.1111/j.1464-410X.2008.07660.x. PMID: 18410444.Shuch, B., Riggs, S. B., LaRochelle, J. C. et al.: Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int, 102: 692, 2008Bigot P., Fardoun T., Bernhard J.C. et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol 2014;32(1):109–14. DOI: 10.1007/s00345-013-1088-1. PMID: 23624719.Bigot, P., Fardoun, T., Bernhard, J. C. et al.: Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World Journal of Urology, 32: 109, 2014Cost N.G., Delacroix S.E. Jr, Sleeper J.P. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011;59(6):912–8. DOI: 10.1016/j.eururo.2011.02.032. PMID: 21367518.Cost, N. G., Delacroix, S. E., Jr., Sleeper, J. P. et al.: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. European Urology, 59: 912, 2011Horn T., Thalgott M.K., Maurer T. et al. Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res 2012;32(5):1729–35. PMID: 22593453.Horn, T., Thalgott, M. K., Maurer, T. et al.: Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res, 32:1729,2012